Neuroendocrine prostate cancer (NEPC) represents a variant of prostate cancer that occurs in response to treatment resistance or, to a much lesser extent, de novo. Unravelling the molecular mechanisms behind transdifferentiation of cancer cells to neuroendocrine-like cancer cells is essential for development of new treatment opportunities. This review focuses on summarizing the role of small molecules, predominantly microRNAs, in this phenomenon. A published literature search was performed to identify microRNAs, which are reported and experimentally validated to modulate neuroendocrine markers and/or regulators and to affect the complex neuroendocrine phenotype. Next, available patients’ expression datasets were surveyed to identify deregul...
Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to orig...
Although several therapeutic options have been shown to improve survival of most patients with prost...
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (C...
Prostate cancer is a condition commonly associated with men worldwide. Androgen deprivation therapy ...
Prostate cancer is featured by its heterogeneous nature, which indicates a different prognosis. Cast...
Prostate carcinoma contain foci of neuroendocrine transdifferentiation, resulting in an increase of ...
Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration...
<div><p>Prostate carcinoma contain foci of neuroendocrine transdifferentiation, resulting in an incr...
Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considera...
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression. Recent findin...
Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to t...
Prostate cancer is the second most common cancer in the United States that affects men today. To bet...
Prostate cancer is one of the most common causes of cancer-related death. The management of prostate...
Prostate cancer (PCa) is the most common non-skin cancer in men worldwide, resulting in significant ...
Prostate cancer (PCa) is the most common non-skin cancer in men worldwide, resulting in significant ...
Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to orig...
Although several therapeutic options have been shown to improve survival of most patients with prost...
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (C...
Prostate cancer is a condition commonly associated with men worldwide. Androgen deprivation therapy ...
Prostate cancer is featured by its heterogeneous nature, which indicates a different prognosis. Cast...
Prostate carcinoma contain foci of neuroendocrine transdifferentiation, resulting in an increase of ...
Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration...
<div><p>Prostate carcinoma contain foci of neuroendocrine transdifferentiation, resulting in an incr...
Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considera...
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression. Recent findin...
Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to t...
Prostate cancer is the second most common cancer in the United States that affects men today. To bet...
Prostate cancer is one of the most common causes of cancer-related death. The management of prostate...
Prostate cancer (PCa) is the most common non-skin cancer in men worldwide, resulting in significant ...
Prostate cancer (PCa) is the most common non-skin cancer in men worldwide, resulting in significant ...
Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to orig...
Although several therapeutic options have been shown to improve survival of most patients with prost...
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (C...